Research and development strategy of vaccine for emergent infectious diseases: Taking the COVID-19 pneumonia as an example

ABSTRACT

To block the continuously global pandemic of novel coronavirus pneumonia (COVID-19 or 2019-nCoV or SARS-CoV-2), more than 300 vaccines have been put into R&D pipelines in tens of countries within two years. At present, vaccines using different technical platforms have been fast approved to use, and widely deployed and vaccinated worldwide due to accelerated medical policies. In this article, the representative vaccines were selected from the main technical routes to analyze the strategy of vaccine R&D and management from the aspects including R&D cooperation, clinical trials, approval and access, production and circulation. We aim to provide reference for the vaccine development and supervision under the circumstance of emergency infectious diseases.